Precision for Medicine, a global leader in biomarker-driven clinical research and development, has announced the opening of its new Japan office, deepening its commitment to the Asia-Pacific region and reinforcing its role as a bridge between local expertise and global development execution.
Japan is the third-largest pharmaceutical market globally and maintains specific expectations for locally derived clinical data in pivotal trials. This requirement has historically created challenges for sponsors incorporating Japan into their development plans.
Precision's Tokyo office and senior leadership embedded in Japan will ensure high quality delivery and consistent global governance while empowering local staff to navigate the regulatory, cultural and operational nuances that define successful trial execution in the market.
"Japan is a vital component of global clinical development," said James Cheong, Senior Vice President, APAC, Precision. "By establishing our own office with dedicated leadership, we eliminate the gap between global trial design and Japanese regulatory expectations, offering our clients consistent global standards with the confidence that comes from genuine local presence."
The Japan office also positions Precision to work directly with biopharmaceutical sponsors, investigators, key external experts and sites, enabling more agile operational delivery and stronger collaborations across Japan's research ecosystem.
The new office opening complements Precision's extensive APAC footprint, which includes over 500 employees and offices in Singapore, Mainland China, Hong Kong, India, South Korea, Taiwan and Australia. Together these operations deliver fully integrated, regionally informed support for clients pursuing global market access.
